Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Applied DNA Sciences, Inc. (APDN) delivers innovative synthetic DNA solutions for therapeutic development, molecular diagnostics, and supply chain security. This news hub provides investors and industry professionals with centralized access to official corporate announcements and verified updates.
Track critical developments across the company's core operations, including advancements in PCR-based DNA production, diagnostic testing services, and anti-counterfeiting technologies. Our curated feed features earnings reports, strategic partnerships, product launches, and regulatory milestones that impact APDN's market position.
Key focus areas include updates on the Linea DNA platform for mRNA therapeutics, CertainT forensic authentication solutions, and clinical testing services. Users benefit from timestamped press releases organized chronologically while maintaining factual accuracy and regulatory compliance.
Bookmark this page for direct access to Applied DNA Sciences' latest financial disclosures, technology patents, and supply chain security initiatives. Check regularly for updates on nucleic acid manufacturing innovations and DNA-based brand protection programs shaping the biotechnology sector.
Applied DNA Sciences (NASDAQ: APDN) has secured approximately $3.6 million in net proceeds after an institutional investor exercised Series B warrants. These warrants were part of a public offering that concluded on August 8, 2022. Each warrant allows the purchase of one share at a price of $4.00 until September 8, 2023. There are currently 2.1 million Series B warrants outstanding, alongside 3 million Series A warrants that remain unexercised until August 9, 2027.
Applied DNA Sciences (NASDAQ: APDN) announced a conference call to discuss third-quarter fiscal results on August 11, 2022, at 4:30 p.m. ET. The call will be hosted by CEO Dr. James A. Hayward and CFO Beth Jantzen. Interested participants can access the call by dialing the provided numbers and are encouraged to connect through the company’s website for the webcast and presentation slides. Applied DNA is focused on developing PCR-based technologies for DNA production and detection across various markets.
Applied DNA Sciences has completed a public offering of 3,000,000 shares at $4.00 each, generating approximately $12 million in gross proceeds. The offering includes Series A and Series B warrants for additional shares, both exercisable at $4.00. H.C. Wainwright & Co. served as the placement agent. The company operates in DNA production and detection technologies, addressing therapeutic, diagnostic, and supply chain security markets.
Applied DNA Sciences, Inc. (NASDAQ: APDN) announced a public offering of 3 million shares of common stock at $4.00 per share, along with two series of warrants. The gross proceeds from this offering are expected to reach $12 million, earmarked for the development of Therapeutic DNA Production and MDx Testing Services, among other corporate purposes. The offering is expected to close around August 8, 2022, subject to customary conditions. H.C. Wainwright & Co. acts as the exclusive placement agent for the offering.
Applied DNA Sciences (NASDAQ: APDN) announced its clinical lab subsidiary, Applied DNA Clinical Labs (ADCL), is validating a PCR-based monkeypox virus test. This test aims to detect the A17L gene specific to monkeypox, differentiating it from other orthopoxviruses. Upon validation, the test will be submitted to the New York State Department of Health for approval and utilized in ADCL's testing services. ADCL plans to leverage its established COVID-19 workflows to ensure efficiency and accuracy in monkeypox testing, enhancing public health response capabilities.
Applied DNA Sciences (NASDAQ: APDN) announced a manuscript publication demonstrating that its LinearDNA vaccine elicited neutralizing antibodies against SARS-CoV-2 in domestic cats. Developed by its subsidiary LineaRx in collaboration with EvviVax, the vaccine showed promising safety and immunogenicity. Additionally, the successful expression of the linDNA vaccine encapsulated in lipid nanoparticles (LNP) was confirmed, paving the way for future animal studies. The company is also exploring out-licensing opportunities for its canine lymphoma vaccine candidate, contingent on successful clinical trials and regulatory approvals.
Applied DNA Sciences (NASDAQ: APDN) announced that Dr. James A. Hayward will present on the benefits of linearDNA as a template for mRNA production at the mRNA-Based Therapeutics Summit in Boston from July 26-28, 2022. His presentation, titled ‘The Future of RNA Therapies Produced from LinearDNA™ Templates,’ is set for July 27 at 4:30 PM EST. The linearDNA method offers advantages over traditional plasmid DNA, including a simplified workflow, less DNA requirement for RNA yields, and removal of problematic sequences. Visit linearxdna.com for more details.
Applied DNA Sciences (NASDAQ: APDN) has launched business development initiatives to promote its LinearDNA™ platform, a cell-free enzymatic DNA production method aimed at enhancing the biotherapeutics sector's efficiency. The company, through its subsidiary LineaRx, is advocating LinearDNA as a viable alternative to traditional plasmid-based DNA production, claiming advantages in speed, purity, flexibility, and scalability. Key applications include DNA vaccines, mRNA production, and gene therapy manufacturing, with preclinical studies showing linDNA's effectiveness.
Applied DNA Sciences (NASDAQ: APDN) is advancing its CertainT® platform as a U.S.-made solution to demonstrate goods’ origins, adhering to the Uyghur Forced Labor Prevention Act (UFLPA) effective from June 21, 2022. The UFLPA bans imports from China's Xinjiang region due to forced labor concerns. The Department of Homeland Security recognizes DNA traceability and isotopic testing as methods to prove compliance. With a focus on securing global supply chains, Applied DNA aims for industry adoption of its technology, which has significant implications for cotton sourcing and overall supply chain security.
Applied DNA Sciences (NASDAQ: APDN) has announced the initiation of its first canine clinical trial for a lymphoma cancer vaccine, based on a peer-reviewed study published in The Journal of Experimental & Clinical Cancer Research. This study supports the use of the company’s LinearDNA™ platform, demonstrating promising preclinical data indicating a strong immune response in canine models. The vaccine targets B-cell lymphoma, the most common cancer in dogs, with plans for a trial to begin this year. This innovation could lead to a conditional license application with the USDA.
